Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Waldenstrom Macroglobulinemia 4Multiple Myeloma 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Congenital Abnormalities 4Sezary Syndrome 3Myeloproliferative Disorders 3Mycosis Fungoides 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Leukemia, Myeloid, Acute 3Burkitt Lymphoma 3Rectal Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Immunoblastic 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Leukemia 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Dendritic Cell Sarcoma, Interdigitating 2

Interventions

Ipilimumab 98pembrolizumab 84Nivolumab 82aldesleukin 51Cyclophosphamide 49Interleukin-2 38fludarabine phosphate 31Vemurafenib 31Dacarbazine 31dabrafenib 29trametinib 28Temozolomide 26fludarabine 25CTLA-4 Antigen 18Bevacizumab 18Radiosurgery 15Paclitaxel 15Carboplatin 14encorafenib 13binimetinib 13Introns 13talimogene laherparepvec 12Radiotherapy 12Interferon alpha-2 12spartalizumab 11cobimetinib 10atezolizumab 10sargramostim 9peginterferon alfa-2b 9montanide ISA 51 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Melanoma × In Situ Hybridization, Fluorescence × Clear all
NCT00466687 2013-07-22

Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma

Vanderbilt-Ingram Cancer Center

Phase 2 Completed
34 enrolled 10 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡